top of page
​
Discover Rubik Therapeutics — advancing CAR-T, radioligand, and ADC cancer treatments using highly selective tumor-specific targets derived from genomic dysregulation.
Rubik Therapeutics develops high-selectivity therapies using its proprietary Oncolinkage platform. Our focus is on best-in-class tumor selectivity, targets optimized for CAR-T, ADC, and radioligand, and a validated platform with partner-ready programs.
-
30+ tumor-selective targets,
-
500K+ addressable patients (US incidence)
-
2 completed licensing deals
We are committed to advancing targeted cancer therapies using genomic precision.
bottom of page